Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease

INTRODUCTION:The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.METHODS:Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.RESULTS:Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year (P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.DISCUSSION:GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.